heart failure left ventricular dysfunction
Conditions
Interventions
None listed
Sponsors
Antoni van Leeuwenhoek Ziekenhuis
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - female; - early invasive BC (TNM stage I - III); - diagnosed and/or treated in the AVL or UMCG; - treated 5 - 7 years or 10 - 12 years ago; - aged 40-50 years at time of therapy; - signed written informed consent.
Exclusion criteria
Exclusion criteria: - history of RT or CT unrelated to BC; - currently under treatment for BC recurrence or second malignancy (including contralateral BC) other than non-melanomatous skin cancer or curatively treated carcinoma in situ of the cervix; - history of cardiac disease (CHF, acute coronary syndrome, coronary revascularization procedure, symptomatic valvular dysfunction, cardiomyopathy or congenital heart defect) before diagnosis and treatment for BC; - mental disability or psychological condition potentially hampering compliance with the study protocol; - insufficient understanding of the Dutch language.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The difference in (sub)clinical cardiovascular damage between patients treated with and without anthracyclines, as measured by left ventricular function parameters. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary parameters are the difference in the prevalence of cardiovascular risk factors, the difference of biochemical measurements related to cardiovascular risk and function, the difference in reproductive history and menopausal status, the difference in quality of life, anxiety, depression and fatigue, the difference in cardiovascular function tests, the difference in physical activity, the difference in cognitive functioning, the difference in presence of cellular senescence and the difference in DNA profiles and telomere length between patients treated with and without anthracyclines. | — |
Countries
Netherlands
Outcome results
None listed